



Minimal side effects
mean maximum client
and patient happiness.



Effective control
of pruritus related to
allergic dermatitis in dogs.²



Topical application
directly treats the
cause of pruritus in dogs.



Reach for Genesis® first.

Available in 8 and 16 oz.

Genesis[®]
TOPICAL SPRAY
(triamcinolone acetonide)



a

Reach for Genesis First



Genesis® Topical Spray (triamcinolone acetonide)

*The only topical therapy demonstrated to be as effective as oral prednisone for flea allergic dermatitis**

- Clinically proven to control the pruritus associated with allergic dermatitis in dogs**
 - Ultra-low concentration (0.015%) of triamcinolone acetonide in a topical spray
 - Dosage can be customized to the patient's changing needs
 - Minimal, mild side effects
 - No antibiotics
 - Dye and fragrance free
- See package insert for complete prescribing information

Genesis should not be used on dogs during pregnancy. Safety has not been demonstrated in dogs less than 8 lbs. or less than 1 year old. The following side effects were similar to placebo and occurred in less than 3.6% of treated dogs: aversion, discomfort, sneezing and watery eyes.

NADA 141-210, Approved by FDA

Genesis® TOPICAL SPRAY

Solution of 0.015% triamcinolone acetonide

FOR TOPICAL USE IN DOGS ONLY

CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS: Genesis Topical Spray is indicated for the control of pruritus associated with allergic dermatitis in dogs.

WARNINGS: User Safety: Wear gloves when applying the product. Spray in a well-ventilated area. If the spray causes irritation to mucous membranes, discontinue use. Keep this and all drugs out of reach of children.

ANIMAL SAFETY: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palates in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia, and anasarca.

PRECAUTIONS: The safety of this product for dogs less than eight pounds or for dogs less than one year of age has not been evaluated. The safety of this product in breeding, pregnant or lactating dogs has not been evaluated (see **WARNINGS**). The safety of long term or repeated use of this product (greater than 28 days) has not been evaluated. Prolonged use or overdosage of any corticosteroid may produce adverse effects. Because absorption of triamcinolone acetonide through topical application on the skin and by licking may occur, dogs receiving triamcinolone acetonide therapy should be observed closely for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. When the product was applied at approximately 6 times the maximum allowable dose (100mL) once daily to normal skin of two dogs for five days, plasma cortisol levels were decreased after the first treatment and response to ACTH was reduced. If adverse clinical signs are observed, treatment should be discontinued. Once the signs have disappeared, treatment can be resumed at a lower dose or frequency of application. If hypersensitivity to the product occurs, treatment should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

ADVERSE REACTIONS: In a field study with Genesis Topical Spray, polyuria was reported in 3 of 57 dogs (5.3%) and polyphagia in 1 of 57 dogs (1.8%). Mild (within reference range) decreases in total leukocyte, lymphocyte and eosinophil counts were also reported. The following local reactions were reported in ≤ 3.6% of 110 dogs treated with Genesis Topical Spray or the product vehicle: aversion/discomfort, sneezing and watery eyes.

For technical information or to report adverse reactions, please call 1-800-338-3659.

© 2005 Virbac AH, Inc. All rights reserved. Genesis is a registered trademark of Virbac AH, Inc. *DeBoer et al. American Journal of Veterinary Research, Vol 63, No. 3, March 2002.

**In the presence of dermatological infections, use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.